2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients

The clinical studies on orelabrutinib covered multiple hematological malignancies, further supporting the excellent efficacy and safety of orelabrutinib.

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.